drugset / Trial / NCT05076877

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

NCT05076877

Phase 1 Completed 20 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the effect of steady-state concentrations of lazertinib on the single-dose pharmacokinetics (PK) of probe substrates (midazolam, rosuvastatin, and metformin) in healthy adult participants.

Timeline

Start
2021-09-17
Primary completion
2022-02-10
Completion
2022-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lazertinib Small molecule Oral
Subject Metformin Small molecule Oral
Subject Midazolam Small molecule Oral
Subject Rosuvastatin Small molecule Oral

Indications

No indication recorded.